RecruitingPhase 2NCT06304103

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kind Pharmaceuticals LLC
Principal Investigator
Yusha Zhu, MD, PhD
Kind Pharmaceuticals LLC
Intervention
AND017(drug)
Enrollment
63 enrolled
Eligibility
18-75 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06304103 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials